ISRCTN31129526
Completed
Not Applicable
Effect of Angiotensin Converting Enzyme Inhibition (ACEI) on C-Reactive Protein (CRP) Levels: The Ramipril CRP Randomized Evaluation (4R Trial)
Sanofi-Aventis (Canada)0 sites400 target enrollmentJanuary 6, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Healthy volunteers with elevated levels of C-Reactive protein
- Sponsor
- Sanofi-Aventis (Canada)
- Enrollment
- 400
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •35\-80 years of age, male or female, free of cardiovascular disease, and baseline CRP greater than 2 mg/l
Exclusion Criteria
- •1\. Structural heart disease or vascular disease
- •2\. Systolic blood pressure greater than 160 or less than 100 mmHg
- •3\. Renal or hepatic dysfunction
- •4\. White blood cell (WBC) count greater than 12,000
- •5\. Chronic inflammatory disease
- •6\. Human Immunodeficiency Virus (HIV)
- •7\. Known sensitivity to ACEI
- •8\. Steroid use
- •9\. Chronic (more than 2 weeks) use of non\-steroidal anti\-inflammatory drugs (NSAIDs)
- •10\. Treatment with:
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
The Effect of Angiotensin Convetring Enzyme Inhibitor on the Quality of Life of Non Hospitalized Patients With Cancer Cachexia in Shiraz University ClinicsGastric cancer.Malignant neoplasm of stomachIRCT2014050511375N3Shiraz University of Midical Sciences40
Recruiting
Not Applicable
Benefit and Harm of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in COVID-19 Patients: A Review Protocol of Systematic Review and Meta-AnalysisThere is a controversial debate regarding how to treat cardiovascular disease in COVID-19 confirmed patients. Ones documented that ACE inhibitor may increase risk of fatal COVID-19 by serving entry site for this virus, on contrary ones documented that ACEi and/or ARB may be beneficial for Acute Lung Injury and cardiovascular protection.JPRN-UMIN000041430Faculty of Medicine, Universitas Airlangga
Terminated
Not Applicable
ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty PatientsAdverse Effects of Angiotensin-converting-enzyme InhibitorsHypotensionNCT01867047Duke University59
Completed
Phase 3
Effect of Angiotensin-converting enzyme and ß-blockers on the prognosis of severe isolated brain traumaS06.2XDiffuse traumatic brain injurySevere isolated brain trauma.IRCT20210514051289N1Esfahan University of Medical Sciences96
Completed
Not Applicable
Angiotensin Converting Enzyme (ACE) inhibition for the preservation of renal function and patient survival in kidney transplantatioChronic kidney disease in renal transplant patientsUrological and Genital DiseasesChronic kidney diseaseISRCTN78129473Ottawa Hospital Research Institute (OHRI) (Canada) - formerly Ottawa Health Research Institute528